You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Johnson and Johnson
AstraZeneca
Colorcon
McKesson

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Gemcabene


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Gemcabene?

Gemcabene is an investigational drug.

There have been 12 clinical trials for Gemcabene. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2016.

The most common disease conditions in clinical trials are Hypercholesterolemia, Hypertriglyceridemia, and Non-alcoholic Fatty Liver Disease. The leading clinical trial sponsors are Gemphire Therapeutics, Inc., Elif Oral, and Emory University.

There are one hundred and eighteen US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Gemcabene
TitleSponsorPhase
Gemcabene for the Treatment of Pediatric NAFLDGemphire Therapeutics, Inc.Phase 2
Gemcabene for the Treatment of Pediatric NAFLDEmory UniversityPhase 2
Study of Gemcabene in Adults With FPLDElif OralPhase 1/Phase 2

See all Gemcabene clinical trials

Clinical Trial Summary for Gemcabene

Top disease conditions for Gemcabene
Top clinical trial sponsors for Gemcabene

See all Gemcabene clinical trials

US Patents for Gemcabene

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gemcabene   Start Trial Methods of reducing risk of cardiovascular disease Gemphire Therapeutics Inc. (Livonia, MI)   Start Trial
Gemcabene   Start Trial Carboxyalkylethers, formulations, and treatment of vascular diseases Warner-Lambert Company (Morris Plains, NJ)   Start Trial
Gemcabene   Start Trial Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE)   Start Trial
Gemcabene   Start Trial Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals Aventis Pharma Deutschland GmbH (Frankfurt Am Main, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Gemcabene

Drugname Country Document Number Estimated Expiration Related US Patent
Gemcabene Australia 2013207423 2032-01-06   Start Trial
Gemcabene Canada 2861643 2032-01-06   Start Trial
Gemcabene China 104136023 2032-01-06   Start Trial
Gemcabene China 110025608 2032-01-06   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Medtronic
Moodys
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.